Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Oxford BioMedica

Oxford BioMedica

Gene and cell therapy group focused on developing life changing treatments for serious diseases.

Oxford BioMedica is a publicly traded, gene and cell therapy group based in Oxford, Oxforshire, UK. The company and its subsidiaries (the "Group") have build a lentiviral delivery platform (LentiVector), which the Group leverages to develop in vivo and ex vivo products, both in-house and with partners. Its portfolio ranges across the areas of oncology, opthalmology, and CNS disorders.

Within its pipeline, Oxford BioMedica has several proprietary products, partnered products, and IP enabled and royalty bearing products. Its proprietary products, which would either be spun-out or licensed out, include:

  • OXB-202 - gene based treatment for corneal graft rejection. Phase 1/2 clinical studies are in preparation.
  • OXB-302 - gene based immunotherapy targeting a range of cancers. Pre-clinical studies are complete.
  • OXB-201 - gene therapy for wet AMD. Phase 1 clinical trials have been completed.
  • OXB-204 - in pre-clinical studies
  • OXB-208 - in pre-clinical studies
  • OXB-103 - in pre-clinical studies

The company's partnered products include:

  • AXO-LENTI-PD - gene therapy threatment for Parkinson's disease. Phase 1/2 clinical studies in preparation. Partnered with Axovant.
  • SAR 422459 - gene therapy for Stargardt disease. Phase 2 clinical studies ongoing. Licensed to Sanofi.
  • SAR 421869 - gene therapy for Usher syndrome type 1B. Phase 1/2a clinical trials ongoing. Licensed to Sanofi.

Additionally, Oxford BioMedica has multiple partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products.



Further Resources


Oxford BioMedica announces further capacity expansion with new facility

Oxford BioMedica plc


Oxford BioMedica to capture 25-30% of lentiviral vector market by 2026, predicts CTO



Ian Sample; photography David Levene
December 21, 2020
the Guardian
From a small discovery to producing at scale, photojournalist David Levene documents the groundbreaking work of the scientists of Oxford University during the development of a vaccine which is now poised for approval by medicines regulators
Alex Keown
November 12, 2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Brandon May
November 10, 2020
Clinical-stage gene therapy company Axovant Gene Therapies is changing its name to Sio Gene Therapies, a move that will likely further distance the company from disappointing results of its Alzheimer's candidate just three years ago.
Michael Le Page, Clare Wilson, Jessica Hamzelou, Adam Vaughan, Conrad Quilty-Harper and Layal Liverpool
September 1, 2020
New Scientist
The latest coronavirus news updated every day including coronavirus cases, the latest news, features and interviews from New Scientist and essential information about the covid-19 pandemic
September 1, 2020
AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmakers COVID-19 vaccine candidate


Golden logo
By using this site, you agree to our Terms & Conditions.